Neos Therapeutics seeks FDA approval for oral ADHD drug; Hospira snags 6 months exlusivity for pediatric intensive care injection;

> Neos Therapeutics filed with the FDA for approval of an extended-release amphetamine for the once-daily oral treatment for ADHD, the first of its kind. The NDA is targeted for completion by October. Release

> The FDA granted Hospira 6 months of pediatric market exclusivity for its Precedex injection, a sedative for patients in an intensive-care environment. Story

> A researcher at UMass Lowell is developing a drug-delivery method combined with an imaging agent that allows for the targeted treatment of breast cancer in HER2-positive women. The National Institutes of Health contributed more than $725,000 to the project. Release

> Vaccine developer Prokarium and the University of Birmingham's Institute of Microbiology pulled in a $600,000 grant to help develop an oral vaccine delivery platform, Vaxonella. Release

> Regulatory entities in Europe approved ThromboGenics' Jetrea, which is a one-time, single intravitreal injection for the breakdown of protein fibers in the treatment of vitreomacular traction. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.